00:29 , Jun 20, 2019 |  BC Innovations  |  Distillery Techniques

Clinically relevant genomic alterations in metastatic breast cancers

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Genomic analyses have identified sets of genetic alterations that could help diagnose hormone receptor (HR)-positive, HER2-negative metastatic breast cancer subtypes and predict associated prognoses. An analysis comparing...
14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
20:08 , Oct 24, 2018 |  BC Innovations  |  Translation in Brief

Common drivers in neuroendocrine tumors

A University of California Los Angeles team is taking steps towards identifying new targets that could be exploited to address treatment-resistant small cell neuroendocrine tumors, regardless of tissue of origin. In a Science paper published...
22:50 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Retinoblastoma Mouse studies suggest inhibiting KDM5A could help treat RB1-deficient retinoblastoma. In an RB1-haploinsufficient mouse model of retinoblastoma, systemic knockout of KDM5A decreased tumor growth and increased survival compared with normal KDM5A expression. Next...
16:13 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with vHL , p53 and RB1 knocked out could be used to help screen therapies for clear cell renal cell carcinoma (ccRCC). In mice, renal epithelial cell-specific knockout of all...
07:00 , Sep 24, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Patient-derived chordoma cell lines for therapeutic screening

Disease models TECHNOLOGY: Cell models Newly generated chordoma cell lines could be used to screen for therapies to treat the rare cancer. Eight new chordoma cell lines established from patient tumor samples recapitulated the markers...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Genetically defined triple-knockout mouse model of high-grade superficial bladder cancer A triple-knockout mouse model of bladder cancer could be useful for studying disease biology and...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma B cell lymphoma 2 (BCL-2; BCL2); cyclin dependent kinase 4 (CDK4); cyclin dependent kinase inhibitor 2A (CDKN2A; INK4a; ARF; p16INK4a); CDKN2B (INK4B;...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

SYKing inhibitors on retinoblastoma

Findings from St. Jude Children's Research Hospital and Washington University in St. Louis researchers show that spleen tyrosine kinase is epigenetically upregulated in retinoblastoma, suggesting that blocking its activity could help treat the disease. 1...
08:00 , Feb 28, 2011 |  BioCentury  |  Emerging Company Profile

Karyopharm: Shushing the usher

In the battle with the human body's natural defense mechanisms, one of the favorite tricks of tumor cells is to use karyopherins to usher tumor suppressor proteins outside the nucleus where they can no longer...